Digestive Health

The medication, glepaglutide, is in development for the treatment of adults with short bowel syndrome with intestinal failure who are dependent on parenteral support.

Recently announced trial results demonstrate the efficacy of the biologic in multiple disease indications.

The risk of developing lymphoma remained nearly the same between patients with Crohn disease and ulcerative colitis.

Pharmacists will likely be the first contact for many affected patients, and they should be able to provide evidence-based advice on how to manage their infection.

The FDA previously accepted the biologic license application for CT-P13 as a subcutaneous formulation.

Currently, the CDC recommends the recombinant zoster vaccine (Shingrix, RZV; GSK) for the prevention of herpes zoster and related complications.

Although psychotherapy is the cornerstone, nutritional education and pharmacotherapies can also help patients recover

Eosinophilic granulomatosis with polyangiitis is a rare and immune-mediate vasculitis that can damage multiple organs and be fatal if left untreated.

Investigators obtained real-world evidence to evaluate the clinical outcomes of non-medical switching from the infliximab (Remicade; Janssen Immunology) to a biosimilar.

Guselkumab (Tremfya; Johnson & Johnson) is the first and only approved fully human and dual-acting monoclonal antibody blocking interleukin-23 and binding to CD64 receptors.

Chronic fatigue is a related symptom with inflammatory bowel disease (IBD).

Although small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) share many of the same symptoms, SIBO affects the small intestine and IBS affects the large intestine.

Inflammatory conditions such as celiac disease can require care consideration and monitoring to manage iron deficiency

The primary end point of clinical remission at week 26 was met, with 36.7% of individuals treated with RHB-104 achieving clinical remission.

A large portion of the population of patients in the United States with GERD have the non-erosive type of the disease.

Unique gut flora were found in children with autism spectrum disorder (ASD).

Mirikizumab met both co-primary end points and all secondary end points at week 52, according to results presented at Digestive Disease Week in Washington DC.

There was no difference observed between adalimumab (Humira; AbbVie) and adalimumab-aacf (Idacio; Fresenius Kabi) for those who switched to the biosimilar.

This holistic approach to healing, grounded in harnessing the therapeutic properties of plants, serves as a bridge between centuries-old traditional wisdom and modern scientific practices.

Melatonin is linked to circadian rhythm, mitochondrial function, and neuroinflammation.

Dedicated clinical trials in IBD cohorts that scrutinized biosimilar use in real-world clinical practice have direct implications on decision making.

Investigators suggested that this difference is caused by a common medication for treatment-resistant schizophrenia.

However, increasing dietary niacin did not reduce risk of mortality from cardiovascular disease, the primary cause of death associated with nonalcoholic fatty liver disease.

Targeted use of ultraviolet light and sporicidal treatment can reduce disease transmission alongside existing interventions.